Emilien B.
- Country
- France
- Department
- Service de Neurologie C
Research Overview
- Evaluation of the Safety and Efficacy of AMX0035 (Phenylbutyrate, Ursodoxicoltaurine) in Adult Patients with Amyotrophic Lateral Sclerosis
- Efficacy and Safety Evaluation of Utreloxastat in Adult Patients with Amyotrophic Lateral Sclerosis: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study
- Phase II Randomized, Double-Blind, Placebo-Controlled Study of NX210c in Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
Data & Insights
Has run more than one trial at 39 of 93 partner sites.
Specializations
Neurodegenerative Disease Research
This investigator specializes in Amyotrophic Lateral Sclerosis (ALS) research, with a particular focus on evaluating novel therapeutic interventions for this progressive neurological condition.
- Disease Progression Assessment
- Biomarker Analysis
- Treatment Innovation
The research explores blood and cerebrospinal fluid markers for monitoring disease progression and treatment response.
Therapeutic Development
The investigator conducts research into multiple therapeutic approaches for ALS management, including combination therapies and novel pharmaceutical compounds.
- Drug Efficacy Studies
- Safety Assessment
- Treatment Combinations
Studies focus on evaluating both established and experimental treatments to enhance patient outcomes.
Clinical Outcomes
Research activities concentrate on measuring therapeutic impacts through functional assessment and survival metrics in ALS patients.
- Ventilation-Free Survival
- Functional Preservation
- Long-term Outcomes
The work encompasses comprehensive evaluation of treatment effects on patient functionality and quality of life.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.